Results 231 to 240 of about 42,337 (292)

Could Old‐School Erythroleukaemia be Back in Style Thanks to TP53?

eJHaem, Volume 6, Issue 4, August 2025.
Jean‐Baptiste Rieu, Alban Canali, Thibault Comont, Léa Ousset, Véronique De Mas   +4 more
wiley   +1 more source

Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology

CA: A Cancer Journal for Clinicians, Volume 75, Issue 4, Page 282-307, July/August 2025.
Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari, Johnson Ung, Jeffrey W. Craig, Kallesh D. Jayappa, Ipsita Pal, David J. Feith, Thomas P. Loughran Jr, Owen A. O’Connor   +7 more
wiley   +1 more source

How we diagnose Myelodysplastic syndromes. [PDF]

Front Oncol
Oster HS, Mittelman M.
europepmc   +1 more source

Outcomes in patients undergoing hematopoietic stem cell transplantation for myelodysplastic syndromes. [PDF]

Blood Cell Ther
Karumathil S, Kulkarni U, Selvarajan S, Lionel S, Devasia AJ, Aboobacker FN, Lakshmi KM, Korula A, Srivastava A, Abraham A, Mathews V, George B.   +11 more
europepmc   +1 more source

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes. [PDF]

Br J Haematol
Papantoniou M, Stergiou I, Giannouli S, Bountziouka C, Kokotis P.   +4 more
europepmc   +1 more source

Innate lymphoid cells in bone marrow and peripheral blood of healthy individuals and in bone marrow of patients with myelodysplastic syndromes. [PDF]

Front Immunol
Bento LC, Cebinelli GM, Bacal NS, Marti LC.   +3 more
europepmc   +1 more source

Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes. [PDF]

PLoS One
Wang MX, Liao CS, Wei XQ, Xie YQ, Han PF, Yu YH.   +5 more
europepmc   +1 more source

Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation. [PDF]

Cancer Med
Liu Q, Xu F, Guo J, Xu F, Huang X, Chen J, Jin J, Zhou L, He Q, Wu D, Song L, Zhang Z, Guo C, Su J, Zhang Y, Yan M, Chang C, Li X, Wu L.   +18 more
europepmc   +1 more source

Kidney involvement in myelodysplastic syndromes. [PDF]

Clin Kidney J
Lafargue MC, Duong Van Huyen JP, Rennke HG, Essig M, Bobot M, Jourde-Chiche N, Sakhi H, Karras A, Boudhabhay I, Brunet P, Boulay H, Grobost V, Philipponnet C, Jeannel J, Chemouny J, Boffa JJ, Braham-Stambouli D, Selamet U, Riella LV, Fain O, Adès L, Fenaux P, Cohen C, Mekinian A.   +23 more
europepmc   +1 more source

Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom. [PDF]

J Blood Med
Drummond M, Finelli C, Kristo F, Kelkar SS, Corman S, Raina R, Ashaye A, Dalal M, Haase D.   +8 more
europepmc   +1 more source